×
About 703 results

ALLMedicine™ Hepatitis D Center

Research & Reviews  248 results

Different evolutionary dynamics of hepatitis B virus genotypes A and D, and hepatitis D...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097355
BMC Infectious Diseases; Karlsen AA, Kyuregyan KK et. al.

May 14th, 2022 - The geographic distribution of the hepatitis B virus (HBV) and the hepatitis D virus (HDV) genotypes is uneven. We reconstructed the temporal evolution of HBV and HDV in Yakutia, one of the regions of Russia most affected by HBV and HDV, in an att...

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
https://clinicaltrials.gov/ct2/show/NCT04535544

May 11th, 2022 - JNJ-73763989 is a liver-targeted antiviral therapeutic for subcutaneous injection designed to treat chronic hepatitis B virus (HBV) infection via ribonucleic acid interference mechanism. This phase 2 study is designed to evaluate safety and effica...

Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide-Re...
https://doi.org/10.1111/apt.16945
Alimentary Pharmacology & Therapeutics; Jachs M, Schwarz C et. al.

May 7th, 2022 - Bulevirtide (BLV) blocks the uptake of the hepatitis D virus (HDV) into hepatocytes via the sodium/bile acid cotransporter NTCP. BLV was conditionally approved by the EMA but real-life data on BLV efficacy are limited. Patients were treated with B...

Entry Inhibitors of Hepatitis B and D Viruses.
https://doi.org/10.1007/978-981-16-8702-0_12 10.1002/hep.24537 10.1128/JVI.00096-07 10.1038/nm0897-866 10.1517/13543780802651583 10.1038/s41598-017-15338-0 10.1002/jmv.23549 10.1128/JVI.75.3.1565-1570.2001 10.1126/science.1598578 10.1006/viro.1995.0002 10.1099/vir.0.004861-0 10.1111/cmi.13205 10.1111/cmi.13205 10.1016/j.virol.2003.09.014 10.1136/gutjnl-2015-310686 10.1136/gutjnl-2015-310686 10.3389/fcimb.2020.00074 10.1073/pnas.1811064116 10.1007/s40265-020-01400-1 10.18632/oncotarget.10241 10.1016/j.jhep.2019.04.010 10.1093/infdis/jis273 10.1371/journal.pone.0058340 10.1128/JVI.01594-09 10.3390/v13010097 10.7554/eLife.26738 10.1007/978-981-13-9151-4_5 10.1016/j.jhep.2019.07.003 10.1016/j.antiviral.2012.12.008 10.1128/JVI.01207-09 10.1016/j.jcmgh.2020.09.001 10.1111/liv.14967 10.1002/hep.31308 10.1002/anie.202102717 10.3389/fmicb.2021.687785 10.1002/hep.27608 10.1101/cshperspect.a004952 10.1128/JVI.01902-09 10.1002/hep.24707 10.1038/sj.emboj.7601841 10.1002/hep.26125 10.1002/hep.26125 10.1002/hep.28013 10.4014/jmb.1703.03066 10.7554/eLife.00049 10.1080/22221751.2019.1625728 10.1038/srep29391 10.1136/gutjnl-2014-308964
Advances in Experimental Medicine and Biology; Yang Y, Xie Y

Apr 13th, 2022 - Human hepatitis B virus (HBV) and hepatitis D virus (HDV) cause acute and chronic infections. The latter poses a serious public health threat as it is the major cause of chronic hepatitis, liver failure, cirrhosis, and hepatocellular carcinoma (HC...

Liver Transplantation in Hepatitis B/Hepatitis D (Delta) Virus Coinfected Recipients.
https://doi.org/10.1097/TP.0000000000004138
Transplantation Martini S, Tandoi F et. al.

Apr 12th, 2022 - Hepatitis D is caused by the hepatitis D virus (HDV); it is the most severe form of viral hepatitis in humans, running an accelerated course to cirrhosis. There is no efficacious therapy, and liver transplantation provides the only therapeutic opt...

see more →

Clinicaltrials.gov  11 results

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
https://clinicaltrials.gov/ct2/show/NCT04535544

May 11th, 2022 - JNJ-73763989 is a liver-targeted antiviral therapeutic for subcutaneous injection designed to treat chronic hepatitis B virus (HBV) infection via ribonucleic acid interference mechanism. This phase 2 study is designed to evaluate safety and effica...

Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
https://clinicaltrials.gov/ct2/show/NCT03600714

Dec 14th, 2021 - Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Based on previous...

A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV R...
https://clinicaltrials.gov/ct2/show/NCT03546621

May 10th, 2021 - This is a multicenter, open-label, randomised, phase II study. The study will be conducted in Russia and Germany. The study is designed to evaluate the benefit of 3 MXB doses versus observation in patients on background therapy with tenofovir, suf...

Hepatitis D Virus Infection Among Hepatitis B Virus Surface Antigen Positive Individuals
https://clinicaltrials.gov/ct2/show/NCT04038372

Jul 30th, 2019 - Globally, about 248 million people are chronic HBV surface antigen carriers, and about 5% of them also had hepatitis delta virus (HDV) infection as well. The prevalence of HBsAg in Egypt is intermediate (2-7%) . Hepatitis D virus (HDV) is an incom...

A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
https://clinicaltrials.gov/ct2/show/NCT01088659

Jan 14th, 2019 - This randomized, single blind study will compare the antiviral effect of Pegasys (pegylated interferon alfa-2a) plus placebo versus Pegasys plus tenofovir in patients with chronic hepatitis D. Patients will be randomized to receive 96 weeks of the...

see more →

News  20 results

Risk Factors Can Help Spot People Who Need Hep D Screening
https://www.medscape.com/viewarticle/940855

Nov 13th, 2020 - NEW YORK (Reuters Health) - Several risk factors associated with hepatitis D virus (HDV) infection can be used to identify people who should be screened, researchers report. "It was interesting to find that the risk factors that were identified in...

Hepatitis D Virus Coinfection Boosts HBV Healthcare Costs
https://www.medscape.com/viewarticle/922853

Dec 20th, 2019 - NEW YORK (Reuters Health) - Hepatitis delta virus (HDV) infection, which occurs only as a co-infection with acute hepatitis B (HBV) or a superinfection with chronic HBV, is associated with higher healthcare utilization and costs than HBV alone, a ...

HDV combo therapy reduces viral loads
https://www.mdedge.com/gihepnews/article/211868/hepatology/hdv-combo-therapy-reduces-viral-loads?channel=346
Will Pass, MDedge News

Nov 8th, 2019 - BOSTON – For most patients with chronic hepatitis D virus (HDV) infection, combination therapy with lonafarnib, ritonavir, and peginterferon may significantly decrease viral loads, based on interim results from the phase IIa LIFT trial. After 6 mo.

Viral Hepatitis Overview: Osmosis Study Video
https://www.medscape.com/viewarticle/895006

Apr 20th, 2018 - What is the hepatitis virus? Well, the hepatitis virus invades liver cells and causes inflammation in the liver tissue. Five hepatitis viruses are recognized: hepatitis A, hepatitis B, hepatitis C, hepatitis D, and hepatitis E. They all have sligh...

Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure
http://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure

What is the purpose of the Surrogate Endpoint Table? FDA’s surrogate endpoint table provides valuable information for drug developers on endpoints that may be considered and discussed with FDA for individual development programs. This table also f...

see more →

Patient Education  2 results see all →